Genetic Testing Market
Report ID: SQMIG35B2244
Report ID: SQMIG35B2244
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35B2244 |
Region:
Global |
Published Date: August, 2025
Pages:
178
|Tables:
118
|Figures:
72
Global Genetic Testing Market size was valued at USD 9.84 Billion in 2024 and is poised to grow from USD 12.1 Billion in 2025 to USD 63.41 Billion by 2033, growing at a CAGR of 23% during the forecast period (2026–2033).
The global genetic testing market growth is driven rapidly in part due to advances in genomics, such as improvements in high-throughput sequencing and bioinformatics. The increased accuracy, efficiency, and affordability of genetic testing have benefited from these innovations. Moreover, many of the new digital health applications (for instance, digital health records) and electronic health records that allow for easier access and navigation of genetic data have also greatly increased the accessibility and ease-of-use of genetic testing.
Instead of being a specialized referral service, healthcare organizations are now routinely screening for prenatal testing. The June 2025 UK initiative allocates GBP 650 million to sequence every newborn, with the aim of identifying over 200 rare disorders at birth. Pilot studies show that non-invasive prenatal testing plus ultrasound has a sensitivity of 88.24% for complex chromosomal abnormalities, which is much higher than that of conventional methods. Early identification of actionable findings helps health systems anticipate better developmental outcomes and lifetime treatment savings. Moreover, the technique creates population databanks that complement reference genomes and facilitate future collaborations. As national insurers codify reimbursement pathways, prenatal genomic panels are predicted to become the norm for obstetric procedures in developed economies.
How is AI Enhancing the Accuracy and Speed of Diagnoses in Genetic Testing?
The market dynamics present in genetic testing cut across the AI-enabled technologies improving the accuracy, efficiency, and speed of the data analysis. In fact, machine learning and deep learning have yielded better precision, more accurate early diagnosis, and improved individualized management by using AI technology.
Market snapshot - 2026–2033
Global Market Size
USD 8.0 Billion
Largest Segment
Offline
Fastest Growth
Online
Growth Rate
23.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global genetic testing market is segmented into technology, product, channel, application, and region. By technology, the market is classified into next generation sequencing, array technology, PCR-based testing, and FISH. Depending on segmentation by product, it is divided into consumables, equipment, and software & services. According to categorization by channel, the market is bifurcated into online and offline. As per the application, it is categorized into ancestry & ethnicity, traits screening, genetic disease carrier status, new baby screening, and health & wellness-predisposition/risk/tendency. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
What Role Do Direct-to-Consumer Tests Play in the Dominance of Predisposition/Risk Analysis?
As per the 2024 genetic testing market analysis, the health & wellness-predisposition/risk/tendency segment led the market with a 52.3% revenue share. The trend illustrates the increasing growth of consumer wellness genomics and predictive genetic testing, due to an increased focus on living a healthy lifestyle and greater awareness of health issues. The two main benefits of genetic testing involve evaluating the risk of potential disease as well as understanding genetic information, such as their child's genetic make-up. It will be especially helpful to those with a family history of genetic disorders. However, the industry faces challenges like the high cost of genomic research equipment and the complexity of predictive and wellness genomics that could limit its growth.
The genetic disease carrier status segment is expected to grow at a notable compound annual growth rate (CAGR) of 22.5% during the forecast period. With advances in genetics, carrier testing, which examines ancestry-based DNA to evaluate the potential for genetic disorders, will continue to rise in popularity. Consequently, it is expected that carrier-based testing will be more necessary, therefore assuring the growth of the genetic testing industry.
How are Private Diagnostic Laboratories Driving Growth in the Offline Segment?
As per the 2024 genetic testing market forecast, the offline segment led the market with the largest revenue share of 62.3%. The rapid advancement of molecular genetic testing technologies has led to a significant expansion of the genetic testing market. These developments have led to an expansion of private diagnostic labs offering a variety of solutions.
One notable genetic testing industry trend in molecular-based testing services is the availability of saliva-based tests and buccal swab collection kits that are sold over the counter in pharmacies, providing customers with convenient options.
The online channel is expected to exhibit the fastest CAGR of 23.6% during the forecast period. This growth is primarily driven by increased funding for molecular biology research, the growing acceptance of personalized medicine, and the increasing popularity of direct-to-consumer testing. Direct-to-consumer companies make genetic testing options easily accessible via over the counter (OTC) and online channels.
To get detailed segments analysis, Request a Free Sample Report
What Role does Government Funding and Healthcare Infrastructure Play in North America’s Market Leadership?
As per the genetic testing market regional analysis, the North American market dominated the market in 2024 with the largest revenue share of 45.38%. The increasing incidence of chronic diseases and the development of diagnostic modalities are key factors contributing to growing demand for diagnostic services. Moreover, with more infectious diseases such as influenza, HIV and tuberculosis presenting continuing increasing evidence, there will be evermore evidence for demand for simple effective detection and treatment options. Additionally, established health infrastructure and government funding for regional research will support demand whereby will progress on the genetic testing market penetration.
U.S. Genetic Testing Market
The genetic testing market is primarily situated in the United States, with a wide application of precision medicine, as well as direct-to-consumer kits made readily available to customers. In an example of this being applied, customers are gaining information on drug-response because of the new expanded pharmacogenomic panel that was FDA approved from 23andMe in 2024. Medical organizations, including the Mayo Clinic, have also used AI-assisted genomic sequencing for rapidly diagnosing rare diseases. The U.S. dominance will be strengthened, backed by authoritative reimbursement systems and the market will demand growth associated with hereditary cancer testing and newborn screening programs.
Canada Genetic Testing Market
Government-funded genomics projects are fueling development in the genetic testing market in Canada. In 2024, Genome Canada launched the All for One precision health initiative, which increased nationwide access to genetic services. Canadian hospitals like SickKids in Toronto developed pediatric genome sequencing programs that accelerated the diagnosis of rare diseases. Increased insurance coverage for hereditary cancer screening and growing partnerships with U.S. biotech companies are driving adoption, which aligns with Canada's emphasis on equitable access to healthcare.
Why is Asia-Pacific Experiencing the Fastest Growth in the Genetic Testing Market?
The genetic testing market in Asia Pacific is expected to expand at the fastest compound annual growth rate (CAGR) of 25.7% during the forecast period. Personalized medicine and the increasing prevalence of chronic and hereditary diseases are continuing to drive the need for genetic testing services. Furthermore, governmental bodies in numerous countries are supporting the market with genomics research funding and integrating genetic testing into public health programs. The expansion of healthcare access in developing economies and the increasing uptake of direct-to-consumer genetic testing will continue to drive overall growth in the Asia Pacific market.
China Genetic Testing Market
The prevalence of genetic disorders, increased healthcare investments, and advancements in medical research are some of the key factors that are expected to drive the China genetic testing market's significant CAGR over the course of the forecast period. The Chinese government's aggressive support of precision medicine and genomics research is driving the demand for genetic testing services.
Japan Genetic Testing Market
The Japanese genetic testing market is anticipated to expand at the fastest CAGR during the forecast period due to advancements in genomic research, rising demand for personalized medicine, and a greater focus on preventive healthcare. The Japanese government has made significant investments in genomic healthcare and has backed attempts to integrate genetic testing into clinical practice and public health programs.
How are Government Initiatives and Research Programs Shaping Genetic Testing Adoption in Europe?
The genetic testing sector in Europe will be among the most lucrative sectors. Demand has increased for clinical and research purposes, particularly as the accuracy, cost, and accessibility of genetic testing is much better than it has ever been since incorporating next-generation sequencing (NGS) and many other improvements/technologies. Market growth is also being driven by the amount of government funding and initiatives for genetic research and improvement of healthcare, coinciding with traditionally increased emphasis on early diagnosis and prevention.
UK Genetic Testing Market
The UK genetic testing market is expected to grow at the fastest compound annual growth rate (CAGR) during the forecast period. The funding by the UK government for genomic health innovation programs has put genomics principles and technologies such as "genetic testing" into practical application and development which translates to speed the use of new genetic tests. The increasing prevalence of genetic disease and greater use of direct-to-consumer genetic testing are fuel factors for market growth.
France Genetic Testing Market
The French genetic testing market is anticipated to grow steadily at a consistent CAGR during the forecast period because of advancements in medical research, a shift in focus towards personalized healthcare, and an increased awareness of genetic disorders. The growth of the French healthcare system's emphasis on precision medicine is a driving force behind genetic testing services, especially in oncology, hereditary diseases, and the prenatal testing.
German Genetic Testing Market
The German genetic testing industry is expected to expand at a significant compound annual growth rate during the forecast period. The country's strong healthcare system and commitment to integrating genomic technologies into clinical practice are driving the adoption of genetic testing, particularly for oncology, rare diseases, and prenatal screening. The market is growing because of government funding for genomics research and the expansion of healthcare initiatives aimed at early disease detection.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Genetic Testing Market Drivers
Advances in Oncology, Payer Adoption, and Precision Medicine
Automation of Workflows and Declining Sequencing Costs
Genetic Testing Market Restraints
Variability in Reimbursement and Evidence Thresholds
Gaps in Consent, Data Privacy, and Interoperability
Request Free Customization of this report to help us to meet your business objectives.
Competitors are struggling for dominance in the genetic testing market, which is competitive. Innovation, product differentiation, and investment for growth are considered key success genetic testing market strategies. With their wide distribution channels, geographic reach, and range of products, these companies can address multiple customer segments across clinical and direct-to-consumer markets. Many industry leaders have invested millions of dollars in research and development to remain competitive in the industry, which has led them to larger, more complicated and more advanced genetic testing solutions.
Top Player’s Company Profile
Recent Developments in Genetic Testing Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, originally meant for individual diagnoses, genetic testing is now evolving toward a fundamental component of modern care. Oncology has forged ahead in the introduction of minimal residual disease (MRD) monitoring and the consequent therapeutic guidance alongside other strides already made in reproductive health, rare diseases, and pharmacogenomics. In the near term, adoption is hampered by reimbursement, privacy, and integration, but as costs decrease and automation improves processes, penetration will also increase. Competition is heating up as platform behemoths bundle ecosystems and clinical labs look to depth of indication, MRD subscriptions and co-development with pharmaceutical companies. Over the next five years, population genomics and decision-support on-the-fly should make testing commonplace in routine pathways, expanding testing volume, and leading to better empirical evidence of equitable access and value-based coverage.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 9.84 Billion |
| Market size value in 2033 | USD 63.41 Billion |
| Growth Rate | 23% |
| Base year | 2024 |
| Forecast period | 2026–2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Genetic Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Genetic Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Genetic Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Genetic Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Genetic Testing Market size was valued at USD 9.84 Billion in 2024 and is poised to grow from USD 12.1 Billion in 2025 to USD 63.41 Billion by 2033, growing at a CAGR of 23% during the forecast period (2026–2033).
Competitors are struggling for dominance in the genetic testing market, which is competitive. Innovation, product differentiation, and investment for growth are considered key success genetic testing market strategies. With their wide distribution channels, geographic reach, and range of products, these companies can address multiple customer segments across clinical and direct-to-consumer markets. Many industry leaders have invested millions of dollars in research and development to remain competitive in the industry, which has led them to larger, more complicated and more advanced genetic testing solutions. '24 genetics', 'EpiMedTech', 'Circle DNA', 'Tellmegen', 'Hitachi High-Tech Corporation', '23andme', 'AncestryDNA', 'MyDNA', 'Everly Well', 'Igenomix', 'VitaGen', 'Myriad Genetics, Inc.', 'Mapmygenome', 'Helix OpCo LLC', 'MyHeritage Ltd.'
Specifically in the field of oncology, physicians are utilizing more liquid biopsies, companion diagnostics, and multigene panels to guide targeted therapies. While payers have covered pharmacogenomics and hereditary cancer once clinical utility and economic value has been demonstrated, hospitals are putting NGS into their tumor boards. Test volumes increase across academic institutions and community networks as real-world data mounts and guidelines (such as NCCN and ESMO) promote more comprehensive testing, thereby reaffirming the ongoing necessity of monitoring and confirmatory assays.
Liquid Biopsy and Minimal Residual Disease (MRD) Monitoring: Blood-based diagnostics are moving from research to routine care, being used for early detection, identifying therapies, and post-treatment monitoring. MRD tests provide ultra-sensitive identification of recurrence for decision-making about variations of adjuvant treatment and de-escalation months before imaging. As ctDNA assays increase in sensitivity and analytics reduce noise, oncologists are doing cancer therapy testing on both tissue and plasma across treatment pathways to recover recurring revenue through longitudinal monitoring versus single diagnostic testing.
What Role does Government Funding and Healthcare Infrastructure Play in North America’s Market Leadership?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
